Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Amsterdam - Delayed Quote EUR

Corbion N.V. (CRBN.AS)

Compare
19.54
-0.05
(-0.26%)
As of 11:10:20 AM GMT+2. Market Open.
Loading Chart for CRBN.AS
  • Previous Close 19.59
  • Open 19.16
  • Bid --
  • Ask --
  • Day's Range 19.16 - 19.80
  • 52 Week Range 18.43 - 26.98
  • Volume 15,044
  • Avg. Volume 99,861
  • Market Cap (intraday) 1.164B
  • Beta (5Y Monthly) 1.08
  • PE Ratio (TTM) 25.38
  • EPS (TTM) 0.77
  • Earnings Date Feb 27, 2025
  • Forward Dividend & Yield 0.64 (3.27%)
  • Ex-Dividend Date May 16, 2025
  • 1y Target Est 26.17

Corbion N.V. provides lactic acid and lactic acid derivatives, other ferment, functional enzyme blends, minerals, vitamins, and algae ingredients worldwide. It offers ingredient solutions for the food, home and personal care, animal nutrition, supplements, pharmaceuticals, medical devices, and bioplastics markets. The company markets its products through a network of sales offices and distributors. The company was formerly known as CSM N.V. and changed its name to Corbion N.V. in October 2013. Corbion N.V. was incorporated in 1919 and is headquartered in Amsterdam, the Netherlands.

www.corbion.com

2,383

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CRBN.AS

View More

Performance Overview: CRBN.AS

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is AEX-Index (^AEX) .

YTD Return

CRBN.AS
9.54%
AEX-Index (^AEX)
0.67%

1-Year Return

CRBN.AS
0.92%
AEX-Index (^AEX)
0.05%

3-Year Return

CRBN.AS
32.62%
AEX-Index (^AEX)
21.50%

5-Year Return

CRBN.AS
16.59%
AEX-Index (^AEX)
87.61%

Compare To: CRBN.AS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CRBN.AS

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    1.14B

  • Enterprise Value

    1.60B

  • Trailing P/E

    25.44

  • Forward P/E

    14.95

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.90

  • Price/Book (mrq)

    1.47

  • Enterprise Value/Revenue

    1.24

  • Enterprise Value/EBITDA

    9.29

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.92%

  • Return on Assets (ttm)

    3.50%

  • Return on Equity (ttm)

    6.52%

  • Revenue (ttm)

    1.29B

  • Net Income Avi to Common (ttm)

    45.9M

  • Diluted EPS (ttm)

    0.77

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    49.3M

  • Total Debt/Equity (mrq)

    65.92%

  • Levered Free Cash Flow (ttm)

    114.12M

Research Analysis: CRBN.AS

View More

Company Insights: CRBN.AS

Research Reports: CRBN.AS

View More

People Also Watch